14.2 Palliative Care, Symptom Management & End-of-Life Decision-Making

14.2 Palliative Care, Symptom Management & End-of-Life Decision-Making

Clinical Scenario: A 77-year-old female with end-stage heart failure (NYHA Class IV, LVEF 15%), chronic kidney disease (baseline eGFR 22 mL/min), and severe vascular dementia is admitted to the ICU with acute hypercapnic respiratory failure and cardiogenic shock requiring intubation, mechanical ventilation, and norepinephrine. Over 72 hours, she develops anuria, refractory lactic acidosis (pH 7.18, lactate 4.8 mmol/L), and progressive multiorgan failure. The patient lacks medical decision-making capacity. Her appointed Durable Power of Attorney for Healthcare (DPOA-HC), her eldest son, presents her authenticated living will refusing permanent mechanical life support when recovery to independent communicative function is impossible. An interdisciplinary conference is convened to transition to comfort-focused end-of-life care, execute terminal extubation, and manage distressing symptoms.

Primary vs. Specialty Palliative Care & Goals of Care Integration

Palliative care is an integral component of critical care that should begin at ICU admission alongside disease-modifying therapies, rather than being reserved solely for terminal withdrawal:

• Primary vs. Specialty Palliative Care: Primary palliative care encompasses core competencies delivered by the primary acute care team, including proactive symptom management, prognostic disclosure, spiritual assessment, and establishing basic goals of care. Specialty palliative care consultation is indicated for refractory symptom crises, intractable family conflict, and ethically complex withdrawal decisions.
• The SPIKES Protocol for Delivering Difficult News: (1) Setting (S): Arrange a private, quiet space with key family decision-makers and interdisciplinary support; silence phones. (2) Perception (P): Elicit the surrogate's current understanding using open-ended questions. (3) Invitation (I): Ask how much detailed medical information the family wishes to receive. (4) Knowledge (K): Deliver prognostic realities clearly and compassionately without jargon. (5) Empathy (E): Acknowledge emotional reactions using NURSE statements (Naming, Understanding, Respecting, Supporting, Exploring). (6) Strategy & Summary (S): Formulate a coordinated care plan focusing on comfort, dignity, and family support.

Advance Directives, Legal Surrogacy Hierarchy & Decision Standards

• Advance Directives & POLST / MOLST: A living will records treatment preferences for the circumstances specified in the document and applicable law. A Durable Power of Attorney for Healthcare (DPOA-HC / Healthcare Proxy) legally appoints an agent to make healthcare choices if capacity is lost; its effective date and activation requirements depend on the document and applicable law. In contrast, Physician Orders for Life-Sustaining Treatment (POLST / MOLST) translate patient preferences into immediate, actionable medical orders signed by a licensed clinician that govern cardiopulmonary resuscitation, medical interventions (comfort, limited, full), and artificial nutrition across emergency medical services and hospitals.
• Surrogate Authority: Verify any valid patient designation, healthcare agent appointment or guardianship order and the applicable state law. Default-surrogate rules differ across states; many prioritize a spouse before other relatives, while others permit selection based on the relationship and knowledge of the patient. Resolve disputed authority with ethics and legal support.
• Substituted Judgment vs. Best Interests: The primary ethical and legal standard is Substituted Judgment, where the surrogate decides what the patient would have chosen based on known prior statements, values, and religious beliefs. If the patient's wishes are entirely unknown and cannot be ascertained, surrogates and clinicians must apply the Best Interests standard, choosing what a reasonable person would select by balancing clinical burdens against potential benefits.

Symptom Management During Dying & Terminal Weaning / Extubation

Withdrawing life-sustaining therapy requires proactive symptom control to prevent distress:

• Ventilator Withdrawal: Terminal weaning involves stepwise downward titration of PEEP, $\text{FiO}_2$, and pressure support over hours. Immediate terminal extubation involves rapid comfort medication boluses followed by immediate endotracheal tube removal. Choose immediate extubation or gradual weaning according to anticipated symptoms, patient preferences, and family discussion. Non-beneficial monitors, arterial lines, and alarms should be silenced and removed.
• Dyspnea & Air Hunger: First-line pharmacotherapy is intravenous opioids (morphine 2–5 mg IV bolus titrated every 10–15 minutes, or fentanyl 25–50 mcg IV bolus in renal failure or hypotension). Opioids blunt central medullary chemoreceptor responses to hypercapnia and hypoxia, reducing tachypnea and accessory muscle use while relieving the sensation of suffocation. Individualize any infusion to prior opioid exposure and comfort, using reassessed boluses for acute distress; respiratory rate alone is not the titration target.
• Anxiety & Agitation: Co-administer intravenous benzodiazepines (midazolam 1–2 mg IV or lorazepam 1–2 mg IV) for acute dyspnea crisis or severe agitation. Midazolam offers rapid onset (1–2 minutes) and short duration for acute distress.
• Terminal Respiratory Secretions ("Death Rattle"): Caused by salivary accumulation in the hypopharynx when swallowing fails in comatose patients. Explain that noisy secretions often do not indicate distress, assess nonverbal discomfort and reposition the patient laterally. Consider a trial of glycopyrrolate (0.2–0.4 mg IV or SC every 4 hours) if needed; response is variable. Because of its quaternary amine structure, it does not cross the blood-brain barrier, avoiding central anticholinergic toxicity and delirium. Scopolamine crosses the blood-brain barrier and may worsen delirium. Avoid routine deep suctioning because it may cause gagging, coughing and mucosal trauma.
• Principle of Double Effect (PDE): Bioethical doctrine establishing that administering high-dose analgesics and sedatives with the sole intention of relieving pain and air hunger is ethically and legally justified, even if it carries the foreseeable secondary risk of respiratory depression or hastened death. Clinicians must never withhold adequate palliative opioid titration due to fear of respiratory depression.

Organ and Tissue Donation

Follow the hospital's agreement for timely referral of imminent deaths and deaths to its organ procurement organization (OPO); the OPO determines medical suitability. Do not independently exclude a potential donor because of age or a diagnostic label. An OPO representative or trained designated requestor initiates the donation request, respecting existing donor authorization and applicable law. Decisions about treatment withdrawal and death determination remain independent of organ recovery. Donation may follow BD/DNC or an approved pathway after circulatory death. For circulatory donation, continue patient-centered comfort care, follow the required observation/declaration protocol and keep recovery personnel separate from withdrawal and declaration roles. Recovery cannot begin before death is established and the required waiting period has elapsed.

Circulatory Death Declaration and Certification

After unsuccessful resuscitation, or when resuscitation is appropriately not undertaken, an authorized clinician confirms death under applicable law and hospital policy. Assess unresponsiveness, absence of spontaneous breathing and absence of circulation by examination, with monitoring/testing when required; a monitor rhythm alone is insufficient. Follow the required observation period for permanent circulatory cessation, especially in a donation pathway. Document the examination, time of declaration and notifications. Pronouncement and cause-of-death certification are distinct tasks, and who may perform each varies by jurisdiction. In certification, record the causal sequence from the immediate disease/injury back to the underlying cause, with contributing conditions separately. “Cardiac arrest” alone describes a terminal mechanism, not the cause of death.

Brain Death Determination (AAN Guidelines)

Brain death/death by neurologic criteria (BD/DNC) is determined through a protocol by a trained, credentialed clinician under applicable law and institutional policy. The 2023 AAN/AAP/CNS/SCCM adult requirements include:

• Prerequisites: Establish a catastrophic, permanent brain injury of known mechanism with consistent neuroimaging and sufficient observation for permanence; wait at least 24 hours after adult hypoxic-ischemic injury. Maintain core temperature≥36°C, SBP≥100 mmHg AND MAP≥75 mmHg, with support if needed. If temperature was≤35.5°C, wait at least 24 hours after rewarming to≥36°C. Exclude severe metabolic/endocrine abnormalities, intoxication and pharmacologic paralysis. Exclude sedative effects using appropriate levels or at least five half-lives, allowing longer with organ dysfunction, obesity or prior hypothermia; a negative routine drug screen alone is insufficient.
• Clinical Examination: Demonstrate coma without brain-mediated motor responses and absent pupillary, corneal, gag and cough reflexes, plus absent oculocephalic (when safe) and bilateral oculovestibular responses. Spinally mediated movements may persist. Do not perform oculocephalic testing when cervical-spine or skull-base integrity is uncertain; follow the guideline’s alternative examination pathway.
• Apnea Test: Ensure acceptable cardiopulmonary risk and normal baseline pH/PaCO2 when chronic hypercarbia is absent. Preoxygenate with 100% oxygen for≥10 minutes to PaO2>200 mmHg. Provide apneic oxygenation using CPAP or an approved technique; adult tracheal insufflation uses 4–6 L/min through a catheter<70% of the tube diameter. Obtain an ABG after 8–10 minutes, earlier if needed. The endpoint requires NO respirations, pH<7.30, PaCO2≥60 mmHg AND a rise≥20 mmHg above pretest baseline. With known chronic hypercarbia, use the known premorbid baseline; suspected chronic hypercarbia with unknown baseline also requires ancillary testing. Abort for spontaneous breaths, SBP<100 or MAP<75 despite support, progressive SpO2<85%, or hemodynamically unstable arrhythmia.
• Ancillary Testing: Use when required examination or apnea components cannot be safely completed or adequately interpreted, including uncorrectable metabolic abnormalities. Complete all testable components first; never use ancillary tests to bypass hypothermia or high sedative levels. Accepted perfusion tests include four-vessel catheter angiography, radionuclide perfusion studies and, in adults, transcranial Doppler. EEG and CT angiography are not accepted ancillary tests under this guideline.